GlucoTrack publishes pro forma combined financial statements following Lokahi Therapeutics merger
GCTK•GlucoTrack published pro forma financial statements reflecting its July 14, 2026, merger with Lokahi Therapeutics. The statements report a $19.7 million net loss for the six months ended June 30, 2026, and $10.62 million in cash and cash equivalents at that date.
1. Financial results
GlucoTrack published pro forma financial statements reflecting its July 14, 2026, merger with Lokahi Therapeutics. For the six months ended June 30, 2026, net loss was $19.7 million, including $13.56 million in operating expenses; Bridge Financing added $3.45 million in expenses, including interest expense and a loss on issuance of convertible notes. The company reported a $28.14 million net loss and no revenue for 2025, and total assets of $54.46 million, including $10.62 million in cash and cash equivalents, as of June 30, 2026.
